DRD2 and lymphoma: While cell lines from certain tissues seem to be equally inhibited by top GPCR drugs (e.g., lung), others are sensitive to specific GPCR drugs, such as lymphoid cancer cells, which are particularly inhibited by DRD2, CHRM1, CHRM2, HTR1A, and HTR2A antagonists (Figure 6E, and Table S13).